Shares of InspireMD, Inc. (NYSE:NSPR) gained 3.76% to $0.20 on Tuesday. The share price is trading in a range of 0.19 – 0.20 (Price in Dollars).
The stock exchanged hands 726,001 shares versus average trading capacity of 1.28M shares, while its shares’ total market worth is $7.36M. InspireMD, Inc. (NYSE:NSPR) shares were trading -97.48% below from the 52-week high price mark of $7.80 and +50.54% above from the 52-week price bottom of $0.13. However the company observed 52 week high price on Jan 8, 2019 and witnessed 52 week low price on Jan 14, 2019.
The company employs 36 people, over the last 12 months has generated revenue of $3.60 million and has a net income of $-11.50 million.
The company’s EPS growth in prior 5 years was 0.00%. In the liquidity ratio analysis; current ratio was 5.50 while debt to equity ratio was 0.00.
InspireMD, Inc. (NYSE: NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details of a new investigator-initiated trial entitled, “Initial Clinical Study of the New CGuard EPS MicroNet Covered Carotid Stent: ‘One Size Fits All,’” at the Leipzig Interventional Course (LINC), which is being held January 22-25, 2019 in Leipzig, Germany.
Prof. Christian Wissgott, from the Institute for Diagnostic and Interventional Radiology/Neuroradiology, Westkuestenklinikum Heide – Academic Teaching Hospital of the Universities of Kiel, Luebeck and Hamburg, presented his findings using a 10mm diameter CGuard™ EPS with SmartFit™ technology across a broad range of carotid artery diameters, under a differentiated concept of “One Size Fits All.”
“One of the keys to successfully treating patients with carotid artery disease is to employ a device that is optimally sized,” commented Prof. Wissgott. “With variations of diameters between the common carotid artery (CCA) and the internal carotid artery (ICA), as well as x-ray images giving significant diameter errors due to projection angles, the correct size choice of a carotid stent is frequently challenging. I believe CGuard™ EPS with SmartFit™ technology overcomes this significant challenge.”
Prof. Wissgott concluded through in-vitro bench testing that the “One Size Fits All” CGuard™ EPS with SmartFit™ technology demonstrated a near flat chronic outward radial force in the range of 5.5 to 9.0mm diameters, meaning the force against a vessel wall in a 5.5mm vessel and that in a 9.0mm vessel are similar. In the subsequent initial clinical study of 30 consecutive routine patients with a range of carotid artery diameters from 9.0 mm in the CCA to 5.2mm in the ICA and diameter changes between the CCA and ICA of 2.6mm, Prof. Wissgott demonstrated that, by using a 10mm diameter CGuard™ EPS in all cases, the “One Size Fits All” SmartFit technology readily adapts to a range of carotid artery diameter changes and offers additional protection against embolic events that can lead to stroke.
The CGuard™ EPS with SmartFit™ was implanted with 100% technical success with no peri-procedural complications and no major or minor strokes at the six-month follow up. Duplex ultrasound, which measures flow through the carotid artery, confirmed that all ECA (external carotid arteries) were fully patent in all cases. In addition, a subgroup of 10 patients underwent DW-MRI follow-up at 30 days and at six months with no new ipsilateral lesions observed.
Dr. James Barry, President and CEO of InspireMD, Inc., commented, “Prof. Wissgott’s in vitro and initial clinical evaluations show the potential of the CGuard™ EPS with SmartFit technology to simplify treating patients with carotid artery disease by using a “One Size Fits All” concept for a majority of carotid artery diameters within patients, and between patients, with excellent clinical results. Additionally, the CGuard™ EPS with SmartFit™ does not forshorten when implanted as do many conventional closed-cell stents and next generation double-layer stents. This allows us to offer what we believe is the easiest-to-use carotid device and procedure available on the market today, while most importantly continuing to provide maximum protection against stroke.”
InspireMD institutional ownership is held at 10.00% while insider ownership was 0.10%. Its EPS was $-57.82 while outstanding shares of the company were 37.89 million. The Company’s Net profit margin was 0.00% while gross profit margin was 27.10%. NSPR last month stock price volatility remained 10.34%.
The stock is now trading at a distance of 7.71% from 20-day simple moving average. The company’s price sits 8.61% above from its 50-day moving average of $0.1728 and -55.36% far from the stock’s 200-day moving average which is $0.2045.
InspireMD, Inc. (NYSE:NSPR) currently has a PEG ratio of 0.00 where as its P/E ratio is 0.00. The company’s price to sales ratio for trailing twelve months is 2.00 and price to book ratio for most recent quarter is 0.70, whereas price to cash per share for the most recent quarter is 0.64. InspireMD, Inc. (NYSE:NSPR)’s price to free cash flow for trailing twelve months is 0.00. Its quick ratio for most recent quarter is 5.20 along with current ratio for most recent quarter of 5.50. Total debt to equity ratio of the company for most recent quarter is 0.00 whereas long term debt to equity ratio for most recent quarter is 0.00. InspireMD, Inc. (NYSE:NSPR) has a Return on Assets of -125.80%. The company currently has a Return on Equity of -200.10% and Return on Investment of -275.30%.